Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
63 hedge funds and large institutions have $220M invested in Dova Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 10 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
5% more funds holding
Funds holding: 60 → 63 (+3)
29% less capital invested
Capital invested by funds: $309M → $220M (-$88.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $1.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$4.92M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.86M |
| 3 |
EU
Emory University
Atlanta,
Georgia
|
+$2.77M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.71M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.9M |
| 2 |
Morgan Stanley
New York
|
-$3.81M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.68M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.55M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$759K |
DOVA Hedge Fund Activity: Q3 2018 in Review
63 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q3 2018, worth a combined $220M — down 29% from $309M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new DOVA positions and 10 closed out — a net gain of 3 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Nexthera Capital, adding an estimated $4.92M. The largest seller was Fidelity Investments, cutting an estimated $8.9M.
- 63 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q3 2018, up from 60 in Q2 2018.
- Funds reported $220M of Dova Pharmaceuticals, Inc. Common Stock stock for Q3 2018, down 29% quarter-over-quarter.
- 13 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 10 closed out, a net change of +3 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was Nexthera Capital, an estimated $4.92M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $8.9M sold.
Based on aggregated 13F filings for Q3 2018.